298 related articles for article (PubMed ID: 6209768)
1. Capsular polysaccharides of Cryptococcus neoformans.
Bhattacharjee AK; Bennett JE; Glaudemans CP
Rev Infect Dis; 1984; 6(5):619-24. PubMed ID: 6209768
[TBL] [Abstract][Full Text] [Related]
2. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
Martinez LR; Moussai D; Casadevall A
Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
[TBL] [Abstract][Full Text] [Related]
3. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
Duro RM; Netski D; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
[TBL] [Abstract][Full Text] [Related]
4. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
Todaro-Luck F; White EH; Reiss E; Cherniak R
Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Mukherjee J; Kozel TR; Casadevall A
J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
Todaro-Luck F; Reiss E; Cherniak R; Kaufman L
Infect Immun; 1989 Dec; 57(12):3882-7. PubMed ID: 2680986
[TBL] [Abstract][Full Text] [Related]
7. Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies.
MacGill TC; MacGill RS; Kozel TR
Infect Immun; 2001 Feb; 69(2):1189-91. PubMed ID: 11160020
[TBL] [Abstract][Full Text] [Related]
8. Soluble polysaccharides of Cryptococcus neoformans.
Cherniak R
Curr Top Med Mycol; 1988; 2():40-54. PubMed ID: 3288362
[No Abstract] [Full Text] [Related]
9. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
Eckert TF; Kozel TR
Infect Immun; 1987 Aug; 55(8):1895-9. PubMed ID: 2440810
[TBL] [Abstract][Full Text] [Related]
10. Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay.
Belay T; Cherniak R
Infect Immun; 1995 May; 63(5):1810-9. PubMed ID: 7537249
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.
Brandt S; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925
[TBL] [Abstract][Full Text] [Related]
12. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
[TBL] [Abstract][Full Text] [Related]
13. A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans.
Probert M; Zhou X; Goodall M; Johnston SA; Bielska E; Ballou ER; May RC
Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670549
[TBL] [Abstract][Full Text] [Related]
14. [Recognition of intact cells from Cryptococcus neoformans by the anti-glucuronoxylomannan 4B3 monoclonal antibody].
Gato Armas R; Martínez Machín G; Rodríguez Sánchez H; Otero González A; Sarracent Pérez J; Illnait Zaragozi MT
Rev Cubana Med Trop; 2006; 58(2):159-61. PubMed ID: 23427436
[TBL] [Abstract][Full Text] [Related]
15. Prevalence in Cryptococcus neoformans strains of a polysaccharide epitope which can elicit protective antibodies.
Cleare W; Mukherjee S; Spitzer ED; Casadevall A
Clin Diagn Lab Immunol; 1994 Nov; 1(6):737-40. PubMed ID: 8556529
[TBL] [Abstract][Full Text] [Related]
16. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis.
Cherniak R; Morris LC; Belay T; Spitzer ED; Casadevall A
Infect Immun; 1995 May; 63(5):1899-905. PubMed ID: 7729900
[TBL] [Abstract][Full Text] [Related]
17. Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans.
MacGill TC; MacGill RS; Casadevall A; Kozel TR
J Immunol; 2000 May; 164(9):4835-42. PubMed ID: 10779792
[TBL] [Abstract][Full Text] [Related]
18. Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide.
Spiropulu C; Eppard RA; Otteson E; Kozel TR
Infect Immun; 1989 Oct; 57(10):3240-2. PubMed ID: 2476401
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen.
Percival A; Thorkildson P; Kozel TR
Clin Vaccine Immunol; 2011 Aug; 18(8):1292-6. PubMed ID: 21697342
[TBL] [Abstract][Full Text] [Related]
20. [The evaluation of the specific type of capsular polysaccharide of Cryptococcus neoformans as an immunogen and positive-control antigen].
Toraño Peraza GT; Rodríguez Acebo W; Martínez Machín G
Rev Cubana Med Trop; 1998; 50(3):207-8. PubMed ID: 10349445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
